Alexander E. Perl - Concepedia

Author

Alexander E. Perl

Also Known As

A E Perl, A Perl, A. E. Perl, A. Perl, A.E. Perl, AE Perl, Alexander E Perl, Alexander E. Perl, Alexander Perl, Ann Mullally

412

Publications

15.6K

Citations

H-Index

Concepts

All Affiliations

University of Pennsylvania Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center The University of Texas MD Anderson Cancer Center University of California, San Francisco

About

Alexander E. Perl is an author at University of Pennsylvania specializing in medicine, oncology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	46	6.9K
2	Health Sciences	19	26	3.2K
3	Blood Transplantation	3	3	87
4	Engineering	1	1	11
5	Biochemistry	1	1	2K

Alexander E. Perl

121

Publications

14.2K

Citations

H-Index

Page 1

	Year	Citations
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate Patrick S. Ward, Jay Patel, David R. Wise, Cancer Cell Somatic VariantBiochemistryMedicineGeneticsInherited Metabolic Disease	2010	2K
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML Alexander E. Perl, Giovanni Martinelli, Jörge E. Cortes, New England Journal of Medicine	2019	1.2K
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia Catherine C. Smith, Qi Wang, Chen-Shan Chin, Nature Hematological MalignancyMedicineMixed-phenotype Acute LeukemiaMalignant Blood DisorderHematology	2012	734
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study Alexander E. Perl, Jessica K. Altman, Jörge E. Cortes, The Lancet Oncology Selective InhibitionHematological MalignancyOncologyMedicinePharmacotherapy	2017	484
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial Jörge E. Cortes, Samer K. Khaled, Giovanni Martinelli, The Lancet Oncology Hematological MalignancyMedicineHematologyClinical TrialsMyeloid Neoplasia	2019	465
ER stress–mediated autophagy promotes Myc-dependent transformation and tumor growth Lori S. Hart, John T. Cunningham, Tatini Datta, Journal of Clinical Investigation	2012	437
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology Martin S. Tallman, Eunice S. Wang, Jessica K. Altman, Journal of the National Comprehensive Cancer Network Hematological MalignancyHealth SciencesMedicineAcute Myeloid LeukemiaMixed-phenotype Acute Leukemia	2019	418
Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia Christine M. McMahon, Timothy T. Ferng, Jonathan Canaani, Cancer Discovery	2019	412
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse Mark J. Levis, Farhad Ravandi, Eunice S. Wang, Blood	2011	395
Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia Sheng Li, Francine E. Garrett-Bakelman, Stephen S. Chung, Nature Medicine Hematological MalignancyChromatinDistinct EvolutionEpigenetic ChangeGenetics	2016	393

Page 1